Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 2055-2067

  Adachi, Jonathan D ^a   Hanley, David A ^b   Lorraine, Joanne K ^c   Yu, Maria ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

acceptance; adherence; compliance; elderly; osteoporosis; teriparatide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ABDOMINAL DISTENSION; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; BREAST CARCINOMA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONTUSION; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FALLING; FATIGUE; FEMALE; GLAUCOMA; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPOGONADISM; INJECTION SITE CONTUSION; LIMB PAIN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NECK PAIN; OPEN STUDY; OSTEOPOROSIS; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PROSTHESIS INFECTION; RHINOPHARYNGITIS; RIB FRACTURE; SELF INJECTION; SELF REPORT; SHOULDER DISLOCATION; SIDE EFFECT; SIGMOID CARCINOMA; STROKE; SUBDURAL HEMATOMA; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TERIPARATIDE; TREATMENT OUTCOME;

EID: 36849048891     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.024     Document Type: Article

References (27)

1. Neer R., Arnaud C., Zanchetta J., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344 (2001) 1434-1441
2. Felsenberg D., Miller P., Armbrecht G., et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37 (2005) 651-654
3. Ettinger B., Black D., Mitlak B., et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. published correction appears in. JAMA 282 (1999) 2124
4. JAMA 282 (1999) 637-645
5. Harris S., Watts N., Genant H., et al. for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled triaI. JAMA. 282 (1999) 1344-1352
6. Reginster J., Minne H., Sorensen O., et al. for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 11 (2000) 83-91
7. Chesnut III C., Silverman S., Andriano K., et al. for the PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. I 09 (2000) 267-276
8. Dempster D., Cosman F., Parisien M., et al. Anabolic actions of parathyroid hormone on bone. published correction appears in. Endocr Rev. 15 (1994) 261
9. Endocr Rev. 14 (1993) 690-709
10. Rosen C., and Bilezikian J. Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 86 (2001) 957-964
11. Dempster D., Cosman F., Kurland E., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res. 16 (2001) 1846-1853
12. Yood R.A., Emani S., Reed J., et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 14 (2003) 965-968
13. Caro J., Ishak K., Huybrechts K., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 15 (2004) 1003-1008
14. Cortet B., and Benichou O. Adherence, persistence, concordance: Do we provide optimal management to our patients with osteoporosis?. Joint Bone Spine 73 (2006) e1-e7
15. Siris E., Harris S., Rosen C., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 81 (2006) 1013-1022
16. Gold D., Alexander I., and Ettinger M. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother. 40 (2006) 1143-1150
17. Weycker D., Macarios D., Edelsberg J., and Oster G. Compliance with drugtherapy for postmenopausal osteoporosis. Osteoporos Int. 17 (2006) 1645-16.52
18. Rossini M., Bianchi G., Di Munno O., et al. for the Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 17 (2006) 914-921
19. Turbi C., Herrero-Beaumont G., Acebes J., et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther. 26 (2004) 245-256
20. Downey T., Foltz S., Boccuzzi S., et al. Adherence and persistence associated with the pharmacologic treatment ofosteoporosis in a managed care setting. South Med J. 99 (2006) 570-575
21. Gaudio A., and Morabito N. Pharmacological management of severe postmenopausal osteoporosis. Drugs Aging. 22 (2005) 405-417
22. World Medical Association Declaration of Helsinki. Available at:. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site] (1989), Ferney-Voltaire, France, WMA. http://www.wma.net.it/bepposaxsoftware/cookbook Accessed April 16, 2007.
23. Brown J., and Josse R. for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management ofosteoporosis in Canada. published corrections appear in. CMAJ. 168 (2003) 400
24. CMAJ. 168 (2003) 676
25. CMAJ. 167 Suppl. 10 (2002) S1-S34
26. Black D., Arden N., Palermo L., et al. for the Study of Osteoporotic Fractures Research Group. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res. 14 (1999) 821-828
27. Nevitt M., Chen P., Kiel D., et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: A meta-analysis. Osteoporos Int. 17 (2006) 1630-1637